barr
viru
ebv
induc
polyclon
activ
almost
infect
cell
small
proport
infect
cell
transform
immort
lymphoblastoid
cell
line
sinc
b
cell
activ
also
ligand
tolllik
receptor
tlr
agonist
via
similar
signal
pathway
like
costimul
molecul
could
result
synergist
enhanc
transform
effici
ebv
studi
stimulatori
effect
cpg
agonist
andor
transform
effici
ebv
normal
human
b
cell
assess
use
limit
dilut
assay
costimul
peripher
blood
mononuclear
cell
pbmc
cpg
increas
significantli
frequenc
ebv
transform
b
cell
p
neither
synergist
addit
effect
observ
tlr
agonist
also
agonist
costimul
cpg
enhanc
prolif
respons
b
cell
infect
ebv
effect
evid
enrich
b
cell
employ
compar
pbmc
promot
effect
tlr
agonist
stimul
impli
ebv
may
take
advantag
gene
induc
tlr
stimul
pathway
viral
latenc
oncogenesi
epsteinbarr
viru
ebv
member
b
lymphotrop
gammaherp
viru
famili
infect
preferenti
human
b
lymphocyt
epitheli
cell
young
rickinson
least
human
popul
worldwid
infect
ebv
middeldorp
et
al
ebv
infect
mediat
bind
class
ii
major
histocompat
complex
mhc
molecul
respons
infecti
mononucleosi
seem
implic
etiolog
number
human
lymphoid
epitheli
malign
burkitt
lymphoma
nasopharyng
carcinoma
hodgkin
lymphoma
diseas
well
nonmalign
disord
system
lupu
erythematosu
sle
middeldorp
et
al
young
rickinson
quan
et
al
vitro
ebv
infect
result
polyclon
b
cell
activ
lead
unlimit
prolifer
transform
b
cell
immort
lymphoblastoid
cell
line
lcl
condit
classifi
type
iii
latenc
infect
young
rickinson
among
identifi
open
read
frame
orf
ebv
genom
nine
protein
includ
six
nuclear
antigen
ebna
lp
three
latent
membran
protein
two
noncod
rna
express
lcl
middeldorp
et
al
young
rickinson
express
induc
morpholog
molecular
chang
mimic
induc
b
cell
receptor
bcr
signal
pathway
kupper
mancao
hammerschmidt
rastelli
et
al
similar
tolllik
receptor
tlr
signal
propos
third
signal
b
cell
activ
could
influenc
wide
rang
immunolog
function
b
cell
upregul
activ
marker
prolifer
cytokin
secret
class
switch
recombin
termin
differenti
antibodi
product
hartmann
krieg
bekeredjiand
jego
vitro
exposur
b
cell
ebv
result
high
infect
rate
small
proport
infect
cell
becom
final
transform
shokrgozar
shokri
traggiai
et
al
sever
protocol
develop
improv
effici
ebv
transform
includ
use
c
irradi
fibroblast
feeder
cell
cultur
medium
supplement
human
plasma
boost
prolifer
transform
b
cell
pelloquin
et
al
manor
prepar
high
titer
ebv
stock
oh
et
al
employ
varieti
mitogen
phytohemagglutinin
henderson
et
al
pokewe
mitogen
bird
et
al
lipopolysaccharid
henderson
et
al
concomit
ebv
infect
promot
effect
b
cell
transform
recent
studi
bcr
colig
shown
promot
ebv
transform
establish
lcl
hur
et
al
howev
littl
known
synergist
effect
ligand
interact
tlr
engag
effici
transform
ligat
b
cell
infect
ebv
lead
promot
viral
latenc
control
ebv
reactiv
downregul
consid
major
viral
activ
lytic
ebv
replic
adler
et
al
moreov
shown
ebv
infect
induc
express
b
cell
consid
critic
transform
surviv
infect
cell
imadom
et
al
howev
controversi
find
report
indic
ligat
restrain
growth
ebvtransform
lcl
switch
viral
transcript
program
full
lymphoblastoid
limit
latenc
program
pokrovskaja
et
al
full
activ
b
cell
infect
ebv
also
trigger
endogen
direct
recognit
ebv
relat
pathogen
associ
molecular
pattern
pamp
via
gaudreault
et
al
martin
et
al
guggemoo
et
al
gargano
et
al
physiolog
condit
exogen
microbi
compon
site
ebv
infect
stenfor
raisanen
iskra
et
al
recent
shown
trigger
probabl
compon
innat
immun
system
inhibit
switch
latent
ebv
infect
lytic
replic
promot
ebvdriven
b
cell
transform
tumor
develop
ladel
et
al
support
observ
agonist
unmethyl
cpg
contain
oligonucleotid
enhanc
synergist
effici
transform
peripher
memori
b
cell
ebv
traggiai
et
al
promot
effect
tlr
agonist
especi
b
cell
transform
studi
extens
studi
potenti
promot
effect
agonist
ligat
alon
combin
ebvdriven
b
cell
prolifer
transform
investig
base
limit
dilut
assay
lda
heparin
peripher
blood
obtain
seven
healthi
adult
volunt
peripher
blood
mononuclear
cell
pbmc
isol
use
histopaqu
sigma
st
loui
mo
usa
densitygradi
centrifug
isol
pbmc
wash
twice
cultur
medium
gibco
grand
island
ny
usa
resuspend
medium
supplement
fetal
bovin
serum
gibco
grand
island
ny
usa
penicillin
iu
streptomycin
lgml
biosera
ringmer
east
sussex
uk
b
cell
isol
pbmc
volunt
use
magneticactiv
cell
sort
mac
neg
select
kit
miltenyi
biotec
bergisch
gladbach
germani
previous
describ
kazemi
et
al
enrich
assess
flow
cytometri
enrich
enrich
cell
viabil
base
trypan
blue
dye
exclus
data
present
ebv
stock
prepar
ebv
stock
prepar
describ
previous
shokri
et
al
briefli
cell
free
supernat
week
old
cultur
cell
line
ncbi
nation
cell
bank
iran
pasteur
institut
iran
tehran
iran
filter
lm
filter
collect
filtrat
centrifug
beckman
ultracentrifug
beckmann
palo
alto
ca
usa
h
result
pellet
resuspend
small
volum
complet
cultur
medium
yield
concentr
viral
load
compar
primari
supernat
concentr
ebv
stock
aliquot
ml
volum
store
cryovial
aliquot
store
concentr
stock
employ
throughout
studi
experi
minim
interassay
variat
time
experi
aliquot
dilut
time
ml
complet
cultur
medium
prior
incub
pbmc
enrich
b
cell
isol
cell
stimul
lgml
cpg
tcg
tcg
ttt
tgt
cgt
ttt
gtc
operon
technolog
cologn
germani
lgml
invivogen
san
diego
ca
usa
agonist
cocultur
inactiv
mous
fibroblast
cell
nation
cell
bank
iran
concomit
ebv
infect
cell
line
employ
studi
display
wide
rang
cell
popul
differ
express
level
assess
flow
cytometri
clone
cell
line
test
number
clone
express
subsequ
clone
highest
express
level
select
experi
h
costimul
period
agit
cell
collect
gentli
pipet
without
dissoci
inactiv
cell
wash
resuspend
complet
cultur
medium
treat
cell
seed
subsequ
well
well
microtit
plate
three
differ
densiti
human
fetal
foreskin
fibroblast
ncbi
nation
cell
bank
iran
fibroblast
cell
inactiv
cirradi
rad
plate
cell
per
well
microtit
plate
overnight
distribut
cell
infect
ebv
cultur
medium
contain
lgml
cyclosporin
prevent
regress
immort
ebvinfect
cell
ebvspecif
memori
lymphocyt
seroposit
individu
follow
week
frequenc
transform
evalu
base
number
well
contain
grow
transform
b
cell
use
standard
ebv
transform
protocol
normal
peripher
pbmc
other
chang
et
al
alreadi
shown
transform
b
cell
establish
within
week
ebv
infect
present
studi
employ
improv
transform
protocol
use
irradi
fetal
fibroblast
feeder
cell
tenfold
concentr
ebv
stock
acceler
transform
process
data
present
nevertheless
check
number
plate
week
ebv
infect
evalu
rate
transform
differ
observ
compar
result
obtain
week
infect
determin
perform
previous
laboratori
studi
carri
estim
frequenc
b
cell
specif
hepat
b
surfac
antigen
hbsag
rhd
antigen
immun
subject
shokrgozar
shokri
pasha
et
al
pbmc
enrich
b
cell
infect
ebv
describ
seed
separ
pbmc
enrich
b
cell
cellswel
microtit
plate
cell
densiti
select
base
pilot
studi
number
normal
individu
enabl
analysi
ebv
transform
frequenc
cell
densiti
distribut
well
frequenc
transform
b
cell
pbmc
evalu
base
poisson
statist
analysi
take
consider
percentag
b
cell
pbmc
determin
flow
cytometri
use
fitcconjug
monoclon
antibodi
ebiosci
san
diego
ca
usa
emerg
lcl
evalu
follow
first
week
actual
number
well
posit
neg
presenc
grow
lcl
plate
determin
microscop
start
third
week
infect
data
transfer
semilogarithm
graph
xand
yax
repres
dilut
cell
neg
fraction
respect
bestfit
line
construct
base
experiment
data
donor
analysi
show
cell
dilut
well
neg
grow
lcl
neg
fraction
averag
one
precursor
b
cell
well
yarchoan
et
al
afterward
effici
ebv
transform
pbmc
estim
base
poisson
statist
analysi
formula
determin
neg
fraction
percentag
b
cell
pbmc
popul
describ
previous
yarchoan
et
al
pasha
et
al
total
pbmc
enrich
b
cell
resuspend
complet
cultur
medium
incub
microtit
plate
humidifi
co
incub
pbmc
b
cell
stimul
lgml
lgml
presenc
absenc
concentr
ebv
stock
stimul
number
cell
cocultur
cirradi
complet
cultur
medium
describ
h
incub
cell
puls
lci
h
thymidin
amersham
aylesburi
uk
harvest
h
later
onto
glassfib
filter
h
thymidin
incorpor
measur
bscintil
counter
previous
describ
shokri
et
al
stimul
index
si
defin
count
per
minut
cpm
radiat
presenc
stimuli
divid
cpm
radiat
absenc
stimuli
frequenc
transform
b
cell
effici
ebv
transform
calcul
base
lda
poisson
analysi
pasha
et
al
differ
frequenc
ebv
transform
presenc
absenc
tlr
agonist
determin
use
descript
chi
squar
test
differ
stimul
index
determin
use
twoindependentsampl
test
p
valu
less
consid
signific
statist
analysi
perform
use
spss
packag
window
spss
inc
chicago
il
usa
peripher
blood
mononuclear
cell
pbmc
seven
adult
donor
stimul
cpg
cell
concomit
ebv
infect
seed
cellswel
densiti
well
microtit
plate
cirradi
feeder
cell
follow
week
stimul
frequenc
transform
evalu
enumer
well
contain
prolifer
transform
lcl
cultur
pbmc
alon
result
appear
grow
lcl
follow
week
cultur
absenc
ebv
prolif
respons
pbmc
cpg
stop
within
week
grow
cell
day
cultur
data
shown
costimul
cpg
result
highest
frequenc
transform
compar
ebv
alon
p
fig
costimul
pbmc
infect
ebv
combin
cpg
neither
induc
addit
effect
significantli
enhanc
transform
effici
ebv
signific
differ
observ
follow
costimul
howev
costimul
pbmc
infect
ebv
combin
tlr
agonist
either
cpg
enhanc
transform
effici
ebv
lesser
extent
tlr
agonist
alon
p
fig
clarifi
direct
indirect
stimulatori
effect
tlr
agonist
ebv
transform
studi
extend
use
enrich
b
cell
pbmc
five
individu
subject
b
cell
infect
ebv
costimul
cpg
cpg
costimul
induc
higher
transform
effici
enrich
b
cell
compar
pbmc
p
fig
absenc
ebv
prolif
respons
b
cell
tlr
agonist
stop
within
week
grow
cell
day
cultur
data
shown
costimul
b
cell
infect
ebv
also
significantli
enhanc
effici
b
cell
transform
ebv
p
fig
frequenc
transform
lymphoblastoid
cell
determin
limit
dilut
assay
base
poisson
statist
analysi
explain
materi
method
infect
pbmc
ebv
alon
gave
transform
frequenc
fig
costimul
cpg
enhanc
transform
effici
ebv
mean
respect
fig
transform
effici
ebv
enrich
b
cell
compar
pbmc
costimul
tlr
agonist
enhanc
frequenc
transform
lead
mean
threefold
increas
cpg
increas
increas
fig
complementari
set
experi
effect
costimul
tlr
agonist
prolifer
pbmc
infect
ebv
assess
shown
fig
cpg
induc
signific
prolifer
pbmc
fig
promot
effect
costimul
tlr
agonist
stimul
effici
ebv
transform
pbmc
pbmc
isol
healthi
adult
infect
ebv
costimul
cpg
andor
treat
cell
seed
cellswel
cultur
plate
inactiv
feeder
cell
presenc
cyclosporin
follow
week
infect
percentag
well
contain
grow
lcl
determin
vertic
horizont
bar
repres
sem
mean
percentag
posit
well
respect
p
p
enrich
b
cell
isol
pbmc
five
healthi
adult
infect
ebv
costimul
cpg
cell
seed
subsequ
cellswel
cultur
plate
irradi
feeder
cell
follow
week
incub
percentag
well
contain
grow
transform
lcl
determin
vertic
horizont
bar
repres
sem
mean
percentag
posit
well
respect
p
p
p
p
respect
enrich
b
cell
p
p
respect
ebv
alon
induc
substanti
prolif
respons
stimul
induc
signific
prolifer
enrich
b
cell
p
pbmc
p
costimul
cpg
boost
prolif
respons
pbmc
infect
ebv
mean
twofold
p
b
cell
infect
ebv
mean
respect
p
increas
reach
statist
signific
like
due
variat
within
sampl
small
sampl
size
enrich
b
cell
collect
five
healthi
subject
infect
ebv
costimul
tlr
agonist
seed
three
differ
cell
densiti
b
cellswel
mean
data
point
obtain
three
cell
densiti
b
cell
infect
ebv
presenc
absenc
tlr
agonist
depict
line
costimul
enhanc
stimul
index
b
cell
pbmc
infect
ebv
differ
statist
signific
b
cell
p
interplay
microb
innat
immun
system
particular
tlr
play
decis
role
fate
infect
primari
ebv
infect
occur
predominantli
infant
toddler
usual
asymptomat
young
rickinson
adult
howev
may
caus
infecti
mononucleosi
im
character
massiv
lymphocyt
prolifer
fever
organomeg
lymph
node
tonsil
liver
spleen
middeldorp
et
al
vitro
infect
ebv
lead
activ
transform
human
b
cell
lcl
young
rickinson
like
herpesvirus
outcom
ebv
infect
predispos
innat
immun
respons
mossman
ashkar
lytic
replic
ebv
block
nuclear
factor
kappa
b
nfjb
master
transcript
factor
relat
innat
immun
respons
gene
overexpress
cell
infect
ebv
brown
et
al
recent
shown
lytic
replic
ebv
inhibit
follow
trigger
signal
infect
cell
ladel
et
al
similar
tlr
stimul
b
cell
via
could
affect
infect
transform
potenti
ebv
adler
et
al
pokrovskaja
et
al
imadom
et
al
studi
effect
tlr
agonist
costimul
transform
effici
ebv
investig
addit
cpg
agonist
time
ebv
infect
improv
significantli
effici
transform
pbmc
enrich
b
cell
infect
ebv
p
fig
lead
threefold
increas
cpg
increas
clonal
outgrowth
b
cell
infect
ebv
base
limit
dilut
assay
fig
promot
effect
evid
particularli
costimul
enrich
b
cell
use
instead
pbmc
impli
induct
immun
effector
cell
within
pbmc
tlr
agonist
potenti
activ
cell
includ
monocyt
nk
cell
dendrit
cell
monocyt
dendrit
cell
may
result
secret
inflammatori
mediat
type
antivir
interferon
ifni
confer
antivir
state
b
cell
lead
lower
transform
rate
b
cell
infect
ebv
megyeri
et
al
tomai
et
al
roda
et
al
addit
stimulatori
effect
cpg
may
arm
natur
killer
nk
cell
erad
b
cell
infect
ebv
sivori
et
al
roda
et
al
costimul
display
promot
effect
ebv
transform
enrich
b
cell
although
effect
less
obtain
tlr
agonist
fig
interestingli
promot
effect
tlr
agonist
lesser
extent
costimul
transform
effici
ebv
seem
correl
prolif
capac
stimul
cell
fig
tlr
agonist
induc
potent
prolif
respons
b
cell
compar
pbmc
fig
costimul
cpg
result
increas
stimul
index
ebvdriven
b
cell
prolifer
respect
prolif
respons
b
cell
stimul
tlr
agonist
alon
last
longer
day
lack
grow
lcl
cell
week
cultur
tlr
stimul
nonstimul
cell
absenc
ebv
indic
outgrowth
ebv
stimul
b
cell
due
reactiv
endogen
ebv
alreadi
exist
small
fraction
b
cell
seroposit
normal
individu
due
tlror
b
cell
prolifer
take
consider
low
number
pbmc
enrich
b
cell
seed
well
limit
dilut
experi
low
frequenc
ebv
infect
b
cell
seroposit
normal
subject
report
less
pbmc
less
per
b
cell
tosato
et
al
chanc
spontan
transform
occurr
seem
extrem
low
use
rtpcr
recent
demonstr
compar
level
mrna
express
ebv
infect
uninfect
b
cell
tlr
agonist
stimul
ebv
infect
substanti
effect
transcript
level
younesi
et
al
thu
differenti
effect
tlr
agonist
prolifer
ebvinfect
b
cell
compar
ebvuntr
b
cell
seem
associ
express
statu
tlr
cell
present
find
regard
support
effect
tlr
agonist
prolifer
b
cell
infect
ebv
report
previous
use
agonist
martin
et
al
recent
promot
potenti
agonist
cpg
effici
ebv
transform
report
iskra
et
al
latter
studi
howev
outgrowth
ebvtransform
lcl
determin
clonal
base
quantit
limit
dilut
assay
flow
cytometr
analysi
perform
determin
increas
forward
side
scatter
transform
cell
rel
rest
b
cell
day
infect
methodolog
oppos
lda
assay
employ
present
studi
could
determin
quantit
transform
effici
ebv
consid
qualit
tool
costimul
plu
tlr
agonist
improv
transform
effici
ebv
fig
part
result
indic
synerg
tlrtlr
signal
report
sever
studi
wagner
et
al
napolitani
et
al
roelof
et
al
et
al
ahonen
et
al
predetermin
properti
may
fluctuat
differ
biolog
condit
inde
effect
tlr
agonist
weaken
addit
though
differ
statist
signific
lower
b
cell
transform
effici
induc
combin
tlr
agonist
compar
tlr
agonist
alon
could
attribut
differ
observ
signal
pathway
activ
via
trif
requir
oeckinghau
et
al
thu
cell
display
appropri
immun
respons
follow
tlr
signal
interestingli
signal
induc
degrad
brown
et
al
therefor
signal
neg
regul
signal
induc
receptor
reli
signal
tlr
furthermor
ebv
infect
result
express
protein
induc
upregul
gene
neg
regul
nfkb
laherti
et
al
induc
signal
cascad
mimic
signal
pathway
mani
aspect
young
rickinson
rastelli
et
al
altogeth
degrad
upregul
gene
upon
stimul
could
weaken
tlr
promot
effect
ebv
transform
surprisingli
agonist
enhanc
transform
effici
ebv
combin
two
agonist
neither
induc
synerg
addit
effect
transform
effici
ebv
although
pair
tlr
agonist
found
display
stronger
vaccin
adjuv
singl
tlr
agonist
costimul
b
cell
immun
cell
combin
tlr
agonist
may
induc
addit
synergist
antagonist
effect
depend
signal
pathway
induc
agonist
zheng
et
al
demonstr
combin
agonist
may
counterregul
intracellular
mechan
differ
immun
cell
pbmc
b
cell
plasmacytoid
dendrit
cell
gorden
et
al
berghof
et
al
marshal
et
al
booth
et
al
use
pair
tlr
agonist
recent
shown
activ
pathway
result
synergist
effect
antagonist
inert
effect
deliv
pair
tlr
agonist
act
signal
pathway
bagchi
et
al
find
similar
result
use
agonist
act
pathway
sinc
tlr
signal
nfjb
pathway
critic
earli
step
immun
respons
modul
nfjb
pathway
import
immunoevas
mechan
hand
given
nfjb
signal
antiapoptot
prolif
effect
virus
ebv
develop
mechan
activ
induc
nfjb
activ
life
cycl
recent
report
ebv
infect
caus
signific
inhibit
stimulatori
effect
agonist
ligand
human
b
lymphocyt
earli
stage
within
first
week
ebv
infect
younesi
et
al
thu
previou
data
togeth
present
find
suggest
ebv
might
employ
nfjb
activ
biphas
manner
physiolog
advantag
hiscott
et
al
earli
stage
ebv
infect
viru
vulner
could
easili
erad
innat
immun
system
nfjb
activ
hamper
subsequ
establish
infect
ebv
take
advantag
prolif
effect
nfjb
pathway
summari
present
find
indic
agonist
enhanc
transform
effici
ebv
perhap
activ
nfjb
signal
pathway
downregul
lytic
replic
ebv
infect
b
cell
ladel
et
al
lower
promot
effect
stimul
effici
ebv
transform
could
attribut
activ
differ
downstream
signal
molecul
follow
interact
benefici
effect
replic
cycl
ebv
although
ligat
b
cell
infect
ebv
shown
promot
viral
latenc
adler
et
al
howev
controversi
result
report
show
diminish
growth
ebvtransform
lcl
follow
ligat
pokrovskaja
et
al
investig
requir
get
insight
biolog
role
ligat
cours
ebv
infect
transform
